Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer

  • Authors:
    • Wataru Fujii
    • Hiroshi Wada
    • Shinichiro Hasegawa
    • Yosuke Mukai
    • Kei Asukai
    • Hirofumi Akita
    • Takahito Sugase
    • Masaaki Yamamoto
    • Tomohira Takeoka
    • Naoki Shinno
    • Hisashi Hara
    • Takeshi Kanemura
    • Naotsugu Haraguchi
    • Junichi Nishimura
    • Masayoshi Yasui
    • Chu Matsuda
    • Takeshi Omori
    • Hiroshi Miyata
    • Masayuki Ohue
    • Masato Sakon
    • Hidenori Takahashi
  • View Affiliations

  • Published online on: May 11, 2022     https://doi.org/10.3892/mco.2022.2542
  • Article Number: 109
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Body composition changes during neoadjuvant therapy and their clinical significance have not been clarified. The present study aimed to investigate body composition changes during neoadjuvant chemoradiation therapy (NACRT) in patients with distal bile duct cancer and the clinical impact on postoperative complications and the prognosis. A total of 16 patients with distal bile duct cancer who underwent curative resection after NACRT were retrospectively evaluated. The area of skeletal muscle, visceral fat and subcutaneous fat on computed tomography and immunological and nutritional indices were assessed before and after NACRT. All 16 patients completed NACRT followed by pancreaticoduodenectomy without mortality. There was no significant change in the skeletal muscle mass index (SMI) during NACRT. Of the 16 patients, nine (56%) were defined as sarcopenic before NACRT, and eight (50%) met the criteria for sarcopenic after NACRT. The SMI and total fat area were significantly associated with postoperative pancreatic fistula (POPF) (P=0.019 and P=0.007, respectively). The patients with sarcopenia had a shorter disease‑free survival time and overall survival time in comparison to patients without sarcopenia (P=0.025 and P=0.115, respectively). In conclusion, NACRT for distal bile duct cancer did not significantly affect the body composition, or the immunological or nutritional indices. Sarcopenia after NACRT was significantly associated with early recurrence in patients with distal bile duct cancer who received NACRT.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 16 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujii W, Wada H, Hasegawa S, Mukai Y, Asukai K, Akita H, Sugase T, Yamamoto M, Takeoka T, Shinno N, Shinno N, et al: Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer. Mol Clin Oncol 16: 109, 2022.
APA
Fujii, W., Wada, H., Hasegawa, S., Mukai, Y., Asukai, K., Akita, H. ... Takahashi, H. (2022). Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer. Molecular and Clinical Oncology, 16, 109. https://doi.org/10.3892/mco.2022.2542
MLA
Fujii, W., Wada, H., Hasegawa, S., Mukai, Y., Asukai, K., Akita, H., Sugase, T., Yamamoto, M., Takeoka, T., Shinno, N., Hara, H., Kanemura, T., Haraguchi, N., Nishimura, J., Yasui, M., Matsuda, C., Omori, T., Miyata, H., Ohue, M., Sakon, M., Takahashi, H."Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer". Molecular and Clinical Oncology 16.6 (2022): 109.
Chicago
Fujii, W., Wada, H., Hasegawa, S., Mukai, Y., Asukai, K., Akita, H., Sugase, T., Yamamoto, M., Takeoka, T., Shinno, N., Hara, H., Kanemura, T., Haraguchi, N., Nishimura, J., Yasui, M., Matsuda, C., Omori, T., Miyata, H., Ohue, M., Sakon, M., Takahashi, H."Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer". Molecular and Clinical Oncology 16, no. 6 (2022): 109. https://doi.org/10.3892/mco.2022.2542